Missouri Senate Bill SB268

Missouri 2023 Regular Session

• Introduced: 1/4/23
• Refer: 2/9/23

Caption

Specifies additional circumstances under which a patient shall be granted an exception to a step therapy protocol required by a health carrier for coverage of a prescription drug

Impact

If enacted, SB268 will significantly impact Missouri state law by mandating that health carriers and benefit plans provide defined pathways for obtaining step therapy overrides. This legislation intends to protect patients from delays in effective treatment, thereby potentially reducing the risk of severe or irreversible health consequences associated with prolonged use of ineffective treatments. The expectation is that health plans will need to revise their protocols and documentation processes to comply with these new requirements, which could lead to changes in administrative procedures within healthcare facilities.

Summary

Senate Bill 268 aims to modify existing regulations regarding prescription drug coverage in instances where a health carrier employs a step therapy protocol. The bill explicitly requires that patients, through their healthcare providers, have access to a clear and accessible process for requesting exceptions to step therapy requirements. This process aims to ensure that if a prescribed medication has demonstrated ineffectiveness or has caused adverse reactions, patients are not unduly required to retry medications that have already proven to be unsuitable for their conditions.

Sentiment

Sentiment around SB268 appears to be largely supportive among healthcare professionals and patient advocacy groups, who view the bill as a necessary reform that prioritizes patient welfare and appropriate medical care. They argue that the existing step therapy protocols often hinder timely access to essential medications. However, there may be concerns from some health carriers about the administrative burdens this bill might impose, reflecting a complex interplay between ensuring patient access and managing cost-efficiency within healthcare systems.

Contention

One notable point of contention regarding SB268 is the potential for increased operational costs for health insurers due to the mandated process for exceptions and the burden of justifying overrides. Critics may argue that while the bill is well-intentioned, it could lead to excessive claims on resources and administrative overhead. In contrast, proponents stress that patient health outcomes should take precedence over cost considerations, highlighting the importance of individualized care in medication management.